{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:33:31Z","timestamp":1775514811885,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["Research program no. 4 Tuberculosis, grant Ricerca Corrente IRCCS"],"award-info":[{"award-number":["Research program no. 4 Tuberculosis, grant Ricerca Corrente IRCCS"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multidrug-resistant tuberculosis (MDR-TB) requires lengthy use of second-line drugs, burdened by many side effects. Hepatitis C virus (HCV) chronic infection increases risk of drug-induced liver injury (DILI) in these patients. Data on MDR-TB patients with concurrent HCV chronic infection treated at the same time with second-line antitubercular drugs and new direct-acting antivirals (DAAs) are lacking. We evaluate if treating at the same time HCV infection and pulmonary MDR-TB is feasible and effective.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Cases presentation<\/jats:title>\n                <jats:p>In this study, we described two cases of patients with pulmonary MDR-TB and concurrent HCV chronic infection cured with DAAs at a Tertiary Infectious Diseases Hospital in Italy. During antitubercular treatment, both patients experienced a DILI before treating HCV infection.<\/jats:p>\n                <jats:p>After DAAs liver enzymes normalized and HCV RNA was undetectable. Then antitubercular regimen was started according to the institutional protocol, drawn up following WHO MDR-TB guidelines. It was completed without further liver side effects and patients were declared cured from both HCV infection and MDR-TB.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We suggest to consider treatment of chronic hepatitis C with DAAs as a useful intervention for reintroduction of second-line antitubercular agents in those patients who developed DILI, reducing the risk of treatment interruption when re-exposed to these drugs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-019-4494-1","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T10:48:33Z","timestamp":1571827713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis"],"prefix":"10.1186","volume":"19","author":[{"given":"Maria","family":"Musso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Gualano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Mencarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Urso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Ghirga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Rianda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Del Nonno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"4494_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/1471-2334-14-333","volume":"14","author":"P Weiss","year":"2014","unstructured":"Weiss P, Chen W, Cook VJ, Johnston JC. Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infect Dis. 2014;14:333. \n                    https:\/\/doi.org\/10.1186\/1471-2334-14-333\n                    \n                  .","journal-title":"BMC Infect Dis"},{"key":"4494_CR2","volume-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO\/HTM\/TB\/2014.11","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO\/HTM\/TB\/2014.11. Geneva: WHO; 2014. Accessed 20 Dec 2018"},{"key":"4494_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mayocp.2013.09.016","volume":"89","author":"MD Leise","year":"2014","unstructured":"Leise MD, Poterucha JJ. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95\u2013106.","journal-title":"Mayo Clin Proc"},{"key":"4494_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","volume":"23","author":"A Tostmann","year":"2008","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192\u2013202.","journal-title":"J Gastroenterol Hepatol"},{"key":"4494_CR5","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","volume":"157","author":"JR Ungo","year":"1998","unstructured":"Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"4494_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1183\/09031936.00188313","volume":"44","author":"C Lange","year":"2014","unstructured":"Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant\/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44:23\u201363.","journal-title":"Eur Respir J"},{"key":"4494_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","volume":"38","author":"G Ramachandran","year":"2015","unstructured":"Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf. 2015;38:253\u201369.","journal-title":"Drug Saf"},{"key":"4494_CR8","first-page":"1382","volume":"8","author":"E Nathanson","year":"2004","unstructured":"Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-plus initiative. Int J Tuberc Lung Dis. 2004;8:1382\u20134.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4494_CR9","doi-asserted-by":"publisher","first-page":"e1328","DOI":"10.1097\/MD.0000000000001328","volume":"94","author":"PH Wu","year":"2015","unstructured":"Wu PH, Lin YT, Hsieh KP, Chuang HY, Sheu CC. Hepatitis C virus infection is associated with an increased risk of active tuberculosis disease: a nationwide population-based study. Medicine (Baltimore). 2015;94:e1328. \n                    https:\/\/doi.org\/10.1097\/MD.0000000000001328\n                    \n                  .","journal-title":"Medicine (Baltimore)"},{"key":"4494_CR10","volume-title":"WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. WHO\/HTM\/TB\/2016.04","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. WHO\/HTM\/TB\/2016.04. Geneva: WHO; 2014. Accessed 20 Dec 2018"},{"key":"4494_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696\u20139.","journal-title":"J Hepatol"},{"key":"4494_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hep.1840200104","volume":"20","author":"The French Metavir Cooperative Study Group","year":"1994","unstructured":"The French Metavir Cooperative Study Group. Intraobserver and inter-observer variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15\u201320.","journal-title":"Hepatology"},{"key":"4494_CR13","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","volume":"18","author":"S Tiberi","year":"2018","unstructured":"Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018;18:e183\u201398.","journal-title":"Lancet Infect Dis"},{"key":"4494_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1055\/s-0032-1333546","volume":"34","author":"CL Daley","year":"2013","unstructured":"Daley CL, Caminero JA. Management of multidrug resistant tuberculosis. Semin Respir Crit Care Med. 2013;34:44\u201359.","journal-title":"Semin Respir Crit Care Med"},{"key":"4494_CR15","doi-asserted-by":"publisher","first-page":"e63057","DOI":"10.1371\/journal.pone.0063057","volume":"8","author":"K Shean","year":"2013","unstructured":"Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One. 2013;8:e63057. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0063057\n                    \n                  .","journal-title":"PLoS One"},{"key":"4494_CR16","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"4494_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.4103\/0970-2113.217569","volume":"34","author":"AI Dela","year":"2017","unstructured":"Dela AI, Tank NKD, Singh AP, Piparva KG. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: a four year retrospective study. Lung India. 2017;34:522\u20136.","journal-title":"Lung India"},{"key":"4494_CR18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.5588\/ijtld.15.0668","volume":"20","author":"SS Lee","year":"2016","unstructured":"Lee SS, Lee CM, Kim TH, et al. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20:800\u20135.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4494_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5588\/ijtld.11.0591","volume":"16","author":"S Keshavjee","year":"2012","unstructured":"Keshavjee S, Gelmanova IY, Shin SS, et al. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int J Tuberc Lung Dis. 2012;16:596\u2013603.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4494_CR20","first-page":"PA2984","volume":"46","author":"E Gurbanova","year":"2015","unstructured":"Gurbanova E, Mehdiyev R, Blondal K, Altraja A. High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons. Eur Respir J. 2015;46:PA2984.","journal-title":"Eur Respir J"},{"key":"4494_CR21","doi-asserted-by":"publisher","unstructured":"Migliori GB, Sotgiu G, Rosales-Klintz S, et al. ERS\/ECDC Statement: European Union standard for tuberculosis care, 2017 update. Eur Respir J. 2018;51(5). \n                    https:\/\/doi.org\/10.1183\/13993003.02678-2017\n                    \n                  .","DOI":"10.1183\/13993003.02678-2017"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4494-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4494-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4494-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:12:50Z","timestamp":1603235570000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4494-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4494"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4494-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"14 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval is not applicable to retrospective review of past clinical cases. All treatments received by the patient were standard of care and were not influenced by this retrospective review. Written informed consent was obtained from both patients for this paper to be published.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from both patients for this paper to be published. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Delia Goletti is an editorial board member for BMC Infectious Diseases. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"882"}}